DBM
MCID: LKM056
MIFTS: 41

Leukemia, Chronic Lymphocytic 2 (DBM)

Categories: Immune diseases, Cancer diseases, Rare diseases, Blood diseases

Aliases & Classifications for Leukemia, Chronic Lymphocytic 2

MalaCards integrated aliases for Leukemia, Chronic Lymphocytic 2:

Name: Leukemia, Chronic Lymphocytic 2 57 29
Leukemia, Chronic Lymphocytic, Susceptibility to, 2 57 13
B-Cell Malignancy, Low-Grade 57 73
Leukemia, Chronic Lymphocytic, B-Cell; Bcll 57
Leukemia, Chronic Lymphocytic, B-Cell 57
Disrupted in B-Cell Malignancy; Dbm 57
Disrupted in B-Cell Malignancy 57
Chronic Lymphocytic Leukemia 73
Clls2 57
Bcll 57
Dbm 57

Characteristics:

OMIM:

57
Inheritance:
autosomal dominant (13q14)


HPO:

32
leukemia, chronic lymphocytic 2:
Inheritance autosomal dominant inheritance


Classifications:



External Ids:

OMIM 57 109543
MedGen 42 C1868683
UMLS 73 C1868683

Summaries for Leukemia, Chronic Lymphocytic 2

MalaCards based summary : Leukemia, Chronic Lymphocytic 2, also known as leukemia, chronic lymphocytic, susceptibility to, 2, is related to leukemia, chronic lymphocytic and prostate cancer, and has symptoms including angina pectoris, chest pain and edema. An important gene associated with Leukemia, Chronic Lymphocytic 2 is CLLS2 (Disrupted In B-Cell Neoplasia). The drugs Chlorambucil and Cyclophosphamide have been mentioned in the context of this disorder. Affiliated tissues include b cells, t cells and bone, and related phenotype is chronic lymphatic leukemia.

Description from OMIM: 109543

Related Diseases for Leukemia, Chronic Lymphocytic 2

Diseases in the Acute Lymphocytic Leukemia family:

Leukemia, Chronic Lymphocytic 2 Leukemia, Chronic Lymphocytic
Leukemia, Chronic Lymphocytic 1 Leukemia, Chronic Lymphocytic 3
Leukemia, Chronic Lymphocytic 4 Leukemia, Chronic Lymphocytic 5
Adult Acute Lymphocytic Leukemia

Diseases related to Leukemia, Chronic Lymphocytic 2 via text searches within MalaCards or GeneCards Suite gene sharing:

# Related Disease Score Top Affiliating Genes
1 leukemia, chronic lymphocytic 10.9
2 prostate cancer 9.8

Symptoms & Phenotypes for Leukemia, Chronic Lymphocytic 2

Symptoms via clinical synopsis from OMIM:

57
Oncology:
b-cell chronic lymphocytic leukemia (cll)


Clinical features from OMIM:

109543

Human phenotypes related to Leukemia, Chronic Lymphocytic 2:

32
# Description HPO Frequency HPO Source Accession
1 chronic lymphatic leukemia 32 HP:0005550

UMLS symptoms related to Leukemia, Chronic Lymphocytic 2:


angina pectoris, chest pain, edema, fatigue

Drugs & Therapeutics for Leukemia, Chronic Lymphocytic 2

Drugs for Leukemia, Chronic Lymphocytic 2 (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 185)
# Name Status Phase Clinical Trials Cas Number PubChem Id
1
Chlorambucil Approved Phase 4,Phase 3,Phase 2,Phase 1 305-03-3 2708
2
Cyclophosphamide Approved, Investigational Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable 50-18-0, 6055-19-2 2907
3
Fludarabine Approved Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable 21679-14-1, 75607-67-9 30751
4
rituximab Approved Phase 4,Phase 3,Phase 2,Phase 1 174722-31-7 10201696
5
Vidarabine Approved, Investigational Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable 24356-66-9 32326 21704
6 Alkylating Agents Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable
7 Anti-Infective Agents Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable
8 Antimetabolites Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable
9 Antimetabolites, Antineoplastic Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable
10 Antineoplastic Agents, Alkylating Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable
11 Antirheumatic Agents Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable
12 Antiviral Agents Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable
13 Immunosuppressive Agents Phase 4,Phase 3,Phase 1,Phase 2,Not Applicable
14 Antibodies Phase 4,Phase 2,Phase 1
15 Antibodies, Monoclonal Phase 4,Phase 1,Phase 2
16 Immunoglobulins Phase 4,Phase 2,Phase 1
17
alemtuzumab Approved, Investigational Phase 3,Phase 2,Phase 1,Not Applicable 216503-57-0
18
Adenosine Approved, Investigational Phase 3,Phase 2,Phase 1 58-61-7 60961
19
Pentostatin Approved, Investigational Phase 3,Phase 2,Phase 1 53910-25-1 40926 439693
20
Cladribine Approved, Investigational Phase 3,Phase 1,Phase 2 4291-63-8 20279
21
Lenograstim Approved, Investigational Phase 3,Phase 2,Phase 1,Not Applicable 135968-09-1
22
Cisplatin Approved Phase 3,Phase 1 15663-27-1 84093 441203 2767
23
Cytarabine Approved, Investigational Phase 3,Phase 1,Phase 2 147-94-4 6253
24
Dexamethasone Approved, Investigational, Vet_approved Phase 3,Phase 2,Phase 1 50-02-2 5743
25
Methylprednisolone Approved, Vet_approved Phase 3,Phase 2,Not Applicable 83-43-2 6741
26
Prednisolone Approved, Vet_approved Phase 3,Phase 2,Not Applicable 50-24-8 5755
27
Lenalidomide Approved Phase 3,Phase 2,Phase 1,Not Applicable 191732-72-6 216326
28
Doxorubicin Approved, Investigational Phase 3,Phase 2,Phase 1 23214-92-8 31703
29
Vincristine Approved, Investigational Phase 3,Phase 2,Phase 1 2068-78-2, 57-22-7 5978
30
Doxil Approved June 1999 Phase 3,Phase 2,Phase 1 31703
31 Antiemetics Phase 3,Phase 2,Phase 1,Not Applicable
32 Anti-Inflammatory Agents Phase 3,Phase 2,Phase 1,Early Phase 1,Not Applicable
33 Antineoplastic Agents, Hormonal Phase 3,Phase 2,Phase 1,Early Phase 1,Not Applicable
34 Autonomic Agents Phase 3,Phase 2,Phase 1,Not Applicable
35 BB 1101 Phase 3,Phase 2,Phase 1
36 Dexamethasone acetate Phase 3,Phase 2,Phase 1 1177-87-3
37 Gastrointestinal Agents Phase 3,Phase 2,Phase 1,Not Applicable
38 glucocorticoids Phase 3,Phase 2,Phase 1,Early Phase 1,Not Applicable
39 HIV Protease Inhibitors Phase 3,Phase 2,Phase 1
40 Hormone Antagonists Phase 3,Phase 2,Phase 1,Early Phase 1,Not Applicable
41 Hormones Phase 3,Phase 2,Phase 1,Early Phase 1,Not Applicable
42 Hormones, Hormone Substitutes, and Hormone Antagonists Phase 3,Phase 2,Phase 1,Early Phase 1,Not Applicable
43 Peripheral Nervous System Agents Phase 3,Phase 2,Phase 1,Not Applicable
44
protease inhibitors Phase 3,Phase 2,Phase 1
45 Anti-Bacterial Agents Phase 3,Phase 2,Phase 1,Not Applicable
46 Antineoplastic Agents, Phytogenic Phase 3,Phase 2,Phase 1
47 Methylprednisolone acetate Phase 3,Phase 2,Not Applicable
48 Methylprednisolone Hemisuccinate Phase 3,Phase 2,Not Applicable
49 Prednisolone acetate Phase 3,Phase 2,Not Applicable
50 Prednisolone hemisuccinate Phase 3,Phase 2,Not Applicable

Interventional clinical trials:

(show top 50) (show all 218)
# Name Status NCT ID Phase Drugs
1 A Study to Compare Mabthera (Rituximab), Fludarabine and Cyclophosphamide to Mabthera and Chlorambucil in Patients With Chronic Lymphocytic Leukemia and Unfavourable Somatic Status Completed NCT01283386 Phase 4 chlorambucil;cyclophosphamide;fludarabine;rituximab [MabThera]
2 Efficacy and Safety of Ofatumumab Retreatment and Maintenance Treatment in Patients With B-cell Chronic Lymphocytic Leukemia (CLL) Completed NCT00802737 Phase 4 Ofatumumab
3 A Study of Rituximab in Combination With Fludarabine and Cyclophosphamide in Participants With Chronic Lymphocytic Leukemia and Favorable Somatic Status Terminated NCT01271010 Phase 4 Cyclophosphamide;Fludarabine;Rituximab
4 Chlorambucil in Treating Patients With Advanced Chronic Lymphocytic Leukemia Unknown status NCT00017108 Phase 3 chlorambucil;cyclophosphamide;fludarabine phosphate
5 Fludarabine (Fludara®) Plus Alemtuzumab (CAMPATH®, MabCampath®) vs Fludarabine Alone in B-Cell Chronic Lymphocytic Leukemia (B-CLL) Patients Completed NCT00086580 Phase 3
6 Fludarabine, Cyclophosphamide, and Rituximab Versus Pentostatin, Cyclophosphamide, and Rituximab in Previously Untreated or Treated B-Cell Chronic Lymphocytic Leukemia Patients Completed NCT00254163 Phase 3 Fludarabine;Cyclophosphamide;Rituximab;Pentostatin
7 Efficacy/Safety of Frontline Alemtuzumab (Campath, MabCampath) vs Chlorambucil in Patients With Progressive B-Cell Lymphocytic Leukemia Completed NCT00046683 Phase 3 alemtuzumab
8 FCR or BR in Patients With Previously Untreated B-Cell Chronic Lymphocytic Leukemia Completed NCT00769522 Phase 3 Bendamustine;Cyclophosphamide;Fludarabine
9 A Study of Maintenance Treatment With MabThera (Rituximab) in Patients With Progressive B-cell Chronic Lymphocytic Leukemia Completed NCT00718549 Phase 3 cladribine;cyclophosphamide;rituximab [MabThera/Rituxan];rituximab [MabThera/Rituxan];rituximab [MabThera/Rituxan]
10 Fludarabine, Cyclophosphamide, and Rituximab or Alemtuzumab in Treating CLL2007 CLL 2007 FMP Completed NCT00564512 Phase 3 cyclophosphamide;fludarabine
11 Fludarabine and Cyclophosphamide With or Without Rituximab in Patients With Previously Untreated Chronic B-Cell Lymphocytic Leukemia Completed NCT00281918 Phase 3 Rituximab;Cyclophosphamide;Fludarabine Phosphate
12 Fludarabine or Observation in Treating Patients With Stage 0, Stage I, or Stage II Chronic Lymphocytic Leukemia Completed NCT00262782 Phase 3 Fludarabine
13 Rituximab, Fludarabine, and Cyclophosphamide or Observation Alone in Treating Patients With Stage 0, Stage I, or Stage II Chronic Lymphocytic Leukemia Completed NCT00275054 Phase 3 Fludarabine;Cyclophosphamide
14 Fludarabine and Cyclophosphamide With or Without Oblimersen in Treating Patients With Relapsed or Refractory Chronic Lymphocytic Leukemia Completed NCT00024440 Phase 3 cyclophosphamide;fludarabine phosphate
15 Autologous Stem Cell Transplantation in Chronic Lymphocytic Leukemia Completed NCT00931645 Phase 3
16 Rituximab Maintenance Versus Observation After First-line Immunochemotherapy by FCR in Older Patients With Chronic Lymphocytic Leukemia Completed NCT00645606 Phase 3
17 Chemotherapy in Treating Patients With Newly Diagnosed Chronic Lymphocytic Leukemia Completed NCT00004218 Phase 3 chlorambucil;cyclophosphamide;doxorubicin hydrochloride;fludarabine phosphate;prednisolone;vincristine sulfate
18 Fludarabine With or Without Cyclophosphamide in Treating Patients With Chronic Lymphocytic Leukemia Completed NCT00003764 Phase 3 cyclophosphamide;fludarabine phosphate
19 A Study to Evaluate the Efficacy and Safety of Lenalidomide as Maintenance Therapy for Patients With B-Cell Chronic Lymphocytic Leukemia (CLL) Following Second Line Therapy Active, not recruiting NCT00774345 Phase 3 Lenalidomide;Placebo
20 Study Of The Effectiveness & Safety Of Lenalidomide Versus Chlorambucil As First Line Therapy For Elderly Patients With B-Cell CLL (The ORIGIN Trial) Active, not recruiting NCT00910910 Phase 3 Lenalidomide;Chlorambucil
21 Early or Delayed Fludarabine and Rituximab in Treating Patients With Previously Untreated Chronic Lymphocytic Leukemia Terminated NCT00513747 Phase 3 fludarabine phosphate
22 Low Dose CdA Combined With Valproic Acid (VPA) in Previously Treated B-cell Chronic Lymphocytic Leukemia(B-CLL) Unknown status NCT01295593 Phase 1, Phase 2 valproic acid and 2-chlorodeoxyadenosine
23 Study of Subcutaneous Campath-1H in Patients With B-Cell CLL and Residual Disease After Chemotherapy Unknown status NCT00800943 Phase 2
24 Pentostatin, Cyclophosphamide, and Rituximab Followed By Lenalidomide in Treating Patients With Relapsed or Refractory B-Cell Chronic Lymphocytic Leukemia Unknown status NCT00074282 Phase 2 cyclophosphamide;lenalidomide;pentostatin
25 Rituximab in Pretreated Elderly or Unfit B-CLL Patients Unknown status NCT01576588 Phase 2 Rituximab;Glucocorticoid
26 Interventional Study on Pentostatin, Cyclophosphamide and Rituximab in Indolent B-Cell Non-Hodgkin-Lymphoma (B-NHL) Unknown status NCT00927797 Phase 2 Cyclophosphamide, Pentostatin, Rituximab
27 Multi-center Trial of Revlimid® and Rituximab, for First-Line Treatment of Chronic Lymphocytic Leukemia (CLL) Unknown status NCT00628238 Phase 2 Lenalidomide and Rituximab;Lenalidomide and Rituximab
28 Subcutaneous Alemtuzumab Combined With Oral Dexamethasone, Followed by Alemtuzumab Maintenance or Allo-SCT in CLL With 17p- or Refractory to Fludarabine Unknown status NCT01392079 Phase 2 Alemtuzumab
29 Alemtuzumab and Clofarabine for Relapsed or Refractory Acute Lymphoblastic Leukemia Unknown status NCT00983528 Phase 1, Phase 2 Clofarabine
30 Imprime PGG, Alemtuzumab, and Rituximab in Treating Patients With High Risk Chronic Lymphocytic Leukemia Unknown status NCT01269385 Phase 1, Phase 2 PGG beta-glucan
31 Ofatumumab, Pentostatin, and Cyclophosphamide in Treating Patients With Untreated Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma Unknown status NCT01024010 Phase 2 pentostatin;cyclophosphamide
32 Dendritic Cell Vaccine in Treating Patients With Indolent B-Cell Lymphoma or Multiple Myeloma Unknown status NCT00937183 Phase 1, Phase 2
33 Denileukin Diftitox in Treating Patients With Non-Hodgkin's Lymphoma Unknown status NCT00026429 Phase 2
34 Study of Bafetinib as Treatment for Relapsed or Refractory B-Cell Chronic Lymphocytic Leukemia (B-CLL) Completed NCT01144260 Phase 2 bafetinib
35 AZD2171 in Treating Patients With Relapsed or Refractory B-Cell Chronic Lymphocytic Leukemia Completed NCT00321724 Phase 2 cediranib maleate
36 Denileukin Diftitox in Treating Patients With Fludarabine-Refractory B-Cell Chronic Lymphocytic Leukemia Completed NCT00082940 Phase 2
37 Fludarabine Combined With Either Alemtuzumab or Rituximab in Treating Patients With Refractory or Relapsed B-Cell Chronic Lymphocytic Leukemia Completed NCT00086775 Phase 2 fludarabine phosphate
38 Subcutaneous Alemtuzumab (CAMPATH®, MabCampath®) in Relapsed/Refractory B-Cell Chronic Lymphocytic Leukemia Completed NCT00328198 Phase 2
39 Bendamustine and Rituximab in Treating Patients With Previously Untreated or Relapsed Chronic Lymphocytic Leukemia Completed NCT00274989 Phase 2 Bendamustine
40 Intensified Rituimab Prephase Before FCR in Untreated B-CLL Completed NCT01370772 Phase 2 Rituximab;Rituximab;Cyclophosphamide;Fludarabine
41 Fludarabine and Monoclonal Antibody Therapy in Treating Patients With Untreated B-cell Chronic Lymphocytic Leukemia Completed NCT00003248 Phase 2 fludarabine phosphate
42 Study to Evaluate the Safety of Subcutaneous Alemtuzumab in Patients With B-Cell Chronic Lymphocytic Leukemia Completed NCT00162851 Phase 2 alemtuzumab
43 Fludarabine, Cyclophosphamide, and Alemtuzumab in Patients With B-cell Chronic Lymphatic Leukemia (B-CLL) Completed NCT00147901 Phase 2 FCCam
44 Alemtuzumab/Fludarabine for Relapsed/Refractory B-cell Chronic Lymphocytic Leukemia (B-CLL) Completed NCT00206726 Phase 2 Alemtuzumab plus Fludarabine
45 Alemtuzumab in Treating Patients With B-Cell Chronic Lymphocytic Leukemia Completed NCT00634881 Phase 1, Phase 2
46 A Safety and Efficacy Trial of a Combination of Bendamustine, Rituximab and Lenalidomide in Patients With Chronic Lymphocytic Leukemia Completed NCT01558167 Phase 1, Phase 2 Bendamustine, Rituximab, Lenalidomide
47 Safety and Dose Ranging Study of ALXN6000 to Treat Relapsing or Refractory CLL or MM Completed NCT00648739 Phase 1, Phase 2 ALXN6000
48 HuMax-CD20 in B-Cell Chronic Lymphocytic Leukemia (B-CLL) Patients Failing Fludarabine and Alemtuzumab Completed NCT00349349 Phase 2 ofatumumab
49 Bendamustine and Mitoxantrone in Treating Patients With Relapsed or Refractory Chronic Lymphocytic Leukemia Completed NCT00274963 Phase 2 bendamustine hydrochloride;mitoxantrone hydrochloride
50 Phase 2 Fludarabine, Cytoxan and FCCAM <Alemtuzumab> in Untreated B-Cell Chronic Lymphocytic Leukemia Completed NCT00230282 Phase 2 Alemtuzumab;Fludarabine;Cytoxan

Search NIH Clinical Center for Leukemia, Chronic Lymphocytic 2

Inferred drug relations via UMLS 73 / NDF-RT 51 :


Genetic Tests for Leukemia, Chronic Lymphocytic 2

Genetic tests related to Leukemia, Chronic Lymphocytic 2:

# Genetic test Affiliating Genes
1 Leukemia, Chronic Lymphocytic 2 29

Anatomical Context for Leukemia, Chronic Lymphocytic 2

MalaCards organs/tissues related to Leukemia, Chronic Lymphocytic 2:

41
B Cells, T Cells, Bone, Bone Marrow, Lymph Node, Myeloid, Endothelial

Publications for Leukemia, Chronic Lymphocytic 2

Articles related to Leukemia, Chronic Lymphocytic 2:

(show top 50) (show all 3406)
# Title Authors Year
1
An Evidence-based Review of Anti-CD20 Antibody-containing Regimens for the Treatment of Patients With Relapsed or Refractory Chronic Lymphocytic Leukemia, Diffuse Large B-cell Lymphoma, or Follicular Lymphoma. ( 29934061 )
2018
2
Cutaneous Mucormycosis Following a Bullous Pemphigoid Flare in a Chronic Lymphocytic Leukemia Patient on Ibrutinib. ( 29760835 )
2018
3
Highly similar genomic landscapes in monoclonal B-cell lymphocytosis and ultra-stable chronic lymphocytic leukemia with low frequency of driver mutations. ( 29449433 )
2018
4
A Chronic Lymphocytic Leukemia Patient with Progressive Multifocal Leukoencephalopathy Caused by John Cunningham Virus. ( 29950535 )
2018
5
Simultaneous finding of chronic lymphocytic leukemia and residual hairy cell leukemia using a lymphocyte-binding anti-CD antibody microarray. ( 29636954 )
2018
6
Cerebral aspergillosis: An emerging opportunistic infection in patients receiving ibrutinib for chronic lymphocytic leukemia? ( 29402474 )
2018
7
Composite Lymphoma as Co-occurrence of Advanced Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma Carrying Trisomy 12 and t(14;18) and Peripheral T-cell Lymphoma. ( 29415977 )
2018
8
Trisomy 12 chronic lymphocytic leukemia expresses a unique set of activated and targetable pathways. ( 29976738 )
2018
9
Cytomegalovirus reactivation can be a cause of DAT-negative hemolytic anemia in patients with chronic lymphocytic leukemia. ( 29911929 )
2018
10
Distribution of Curcumin and THC in Peripheral Blood Mononuclear Cells Isolated from Healthy Individuals and Patients with Chronic Lymphocytic Leukemia. ( 29277764 )
2018
11
Chronic lymphocytic leukemia cells acquire regulatory B-cell properties in response to TLR9 and CD40 activation. ( 29450641 )
2018
12
Necrobiotic xanthogranuloma associated with chronic lymphocytic leukemia. ( 29485184 )
2018
13
Current perspectives on the role of chemotherapy in chronic lymphocytic leukemia. ( 28565930 )
2018
14
Paraneoplastic Pemphigus Associated with B-cell Chronic Lymphocytic Leukemia Treated with Ibrutinib and Rituximab. ( 29526963 )
2018
15
Idelalisib impairs T-cell-mediated immunity in chronic lymphocytic leukemia. ( 29976737 )
2018
16
Gamma heavy chain disease evolving during the progression of chronic lymphocytic leukemia. ( 29315075 )
2018
17
PD-1 Expression in Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (CLL/SLL) and Large B-cell Richter Transformation (DLBCL-RT): A Characteristic Feature of DLBCL-RT and Potential Surrogate Marker for Clonal Relatedness. ( 29762141 )
2018
18
Safety of obinutuzumab alone or combined with chemotherapy for previously untreated or relapsed/refractory chronic lymphocytic leukemia in the Phase 3b GREEN study. ( 29976743 )
2018
19
Transformation of Chronic Lymphocytic Leukemia (CLL) into B-cell Acute Lymphoblastic Leukemia (ALL). ( 29437555 )
2018
20
Quercetin Therapy for Selected Patients with PIM1 Kinase-Positive Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma: A Pilot Study. ( 29444501 )
2018
21
Autologous T cells expressing the oncogenic transcription factor KLF6-SV1 prevent apoptosis of chronic lymphocytic leukemia cells. ( 29432497 )
2018
22
A catalytically inactive gelatinase B/MMP-9 mutant impairs homing of chronic lymphocytic leukemia cells by altering migration regulatory pathways. ( 29080742 )
2018
23
Prevalence of cutaneous viral infections in incident cutaneous squamous cell carcinoma detected among chronic lymphocytic leukemia and hematopoietic stem cell transplant patients. ( 28679298 )
2018
24
Refractory Abdominal Pain in a Patient with Chronic Lymphocytic Leukemia: Be Wary of Acquired Angioedema due to C1 Esterase Inhibitor Deficiency. ( 29545957 )
2018
25
Challenges in assessing the real incidence of chronic lymphocytic leukemia: 16A years of epidemiological data from the province of Girona, Spain. ( 29383469 )
2018
26
Targeting the IL-17/IL-6 axis can alter growth of Chronic Lymphocytic Leukemia in vivo/in vitro. ( 29353760 )
2018
27
Disseminated cerebral toxoplasmosis in a patient with chronic lymphocytic leukemia. ( 29428267 )
2018
28
Mixed-species RNAseq analysis of human lymphoma cells adhering to mouse stromal cells identifies a core gene set that is also differentially expressed in the lymph node microenvironment of mantle cell lymphoma and chronic lymphocytic leukemia patients. ( 29449436 )
2018
29
Paraneoplastic pemphigus with anti-desmocollin 3 autoantibodies and chronic lymphocytic leukemia. ( 29599682 )
2018
30
Synchronous hairy cell leukemia and chronic lymphocytic leukemia: a case report with a brief review of literature. ( 29963523 )
2018
31
Treatment Sequencing in a Chronic Lymphocytic Leukemia Patient with Central Nervous System Involvement. ( 29977629 )
2018
32
Siglec-6 on chronic lymphocytic leukemia cells is a target for post-allogeneic hematopoietic stem cell transplantation antibodies. ( 29980538 )
2018
33
Ibrutinib treatment of a patient with relapsing chronic lymphocytic leukemia and sustained remission of Richter syndrome. ( 28708231 )
2017
34
Clonal evolution leading to ibrutinib resistance in chronic lymphocytic leukemia. ( 28049639 )
2017
35
Plasma matrix metalloprotease 9 correlates with blood lymphocytosis, leukemic cell invasiveness, and prognosis in B-cell chronic lymphocytic leukemia. ( 28240053 )
2017
36
The distribution and potential prognostic value of SMAD protein expression in chronic lymphocytic leukemia. ( 28349818 )
2017
37
Plasmablastic Lymphoma with Coexistence of Chronic Lymphocytic Leukemia in an Immunocompetent Patient: A Case Report and Mini-Review. ( 29387498 )
2017
38
Treatment of chronic lymphocytic leukemia/small lymphocytic lymphoma presenting simultaneously with acquired hemophilia and warm autoimmune hemolytic anemia. ( 28670081 )
2017
39
Presentation of Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma in a Warthin Tumor: Case Report and Literature Review. ( 28978260 )
2017
40
Paraneoplastic pemphigus associated with chronic lymphocytic leukemia: A case report. ( 28225504 )
2017
41
Venetoclax for the treatment of patients with chronic lymphocytic leukemia. ( 28492339 )
2017
42
Learning from the Failures of Drug Discovery in B-Cell Non-Hodgkin Lymphomas and Perspectives for the Future: Chronic Lymphocytic Leukemia and Diffuse Large B-Cell Lymphoma as Two Ends of a Spectrum in Drug Development. ( 28494631 )
2017
43
Ectopic ILT3 controls BCR-dependent activation of Akt in B-cell chronic lymphocytic leukemia. ( 28931525 )
2017
44
Use of minimal residual disease assessment in the treatment of chronic lymphocytic leukemia. ( 28509580 )
2017
45
Possible Role of Polymorphisms in TNFA, NFKB1, and CASP8 Gene Promoter Areas in the Development of Chronic Lymphocytic Leukemia. ( 28361429 )
2017
46
Update of the Grupo EspaA+ol de Leucemia LinfocA-tica CrA^nica clinical guidelines of the management of chronic lymphocytic leukemia. ( 28236475 )
2017
47
New drug discovery approaches targeting recurrent mutations in chronic lymphocytic leukemia. ( 28776453 )
2017
48
Response of renal cell carcinoma to ibrutinib, a bruton tyrosine kinase inhibitor, in a patient treated for chronic lymphocytic leukemia. ( 28503240 )
2017
49
Chronic lymphocytic leukemia with isochromosome 17q: An aggressive subgroup associated with TP53 mutations and complex karyotypes. ( 28888994 )
2017
50
Common nonmutational<i>NOTCH1</i>activation in chronic lymphocytic leukemia. ( 28314854 )
2017

Variations for Leukemia, Chronic Lymphocytic 2

Expression for Leukemia, Chronic Lymphocytic 2

Search GEO for disease gene expression data for Leukemia, Chronic Lymphocytic 2.

Pathways for Leukemia, Chronic Lymphocytic 2

GO Terms for Leukemia, Chronic Lymphocytic 2

Sources for Leukemia, Chronic Lymphocytic 2

3 CDC
7 CNVD
9 Cosmic
10 dbSNP
11 DGIdb
17 ExPASy
19 FMA
28 GO
29 GTR
30 HGMD
31 HMDB
32 HPO
33 ICD10
34 ICD10 via Orphanet
35 ICD9CM
36 IUPHAR
37 KEGG
38 LifeMap
40 LOVD
42 MedGen
44 MeSH
45 MESH via Orphanet
46 MGI
49 NCI
50 NCIt
51 NDF-RT
54 NINDS
55 Novoseek
57 OMIM
58 OMIM via Orphanet
62 PubMed
64 QIAGEN
69 SNOMED-CT via HPO
70 SNOMED-CT via Orphanet
71 TGDB
72 Tocris
73 UMLS
74 UMLS via Orphanet
Content
Loading form....